KB407 (Nebulization)

BIOLOGICAL2 trials

Sponsors

Krystal Biotech, Inc.

Conditions

Cystic Fibrosis

Phase 1

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

WithdrawnNCT05095246

Krystal Biotech, Inc.Cystic Fibrosis

Start: 2022-03-08End: 2024-10-30Updated: 2023-08-14

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

RecruitingNCT05504837

Krystal Biotech, Inc.Cystic Fibrosis

Start: 2023-06-30End: 2027-03-01Target: 20Updated: 2026-05-07